MedPath

Risk of Metabolic Adaptation After Weight Loss

Not Applicable
Suspended
Conditions
Obesity
Weight Loss
Interventions
Other: phentermine-topiramate combined with lifestyle intervention
Other: lifestyle intervention with meal replacement program
Registration Number
NCT05139420
Lead Sponsor
Medical College of Wisconsin
Brief Summary

This study aims at identifying the neurohormonal biomarkers that characterize individuals at risk of greater metabolic adaptation to weight loss, a disproportionate decline in resting metabolic rate during and after weight loss.

Detailed Description

Not available

Recruitment & Eligibility

Status
SUSPENDED
Sex
All
Target Recruitment
60
Inclusion Criteria

BMI > or = 30 any ethnicity

Exclusion Criteria

weight > or = 400 lbs.

diabetes (type 2 or type 1)

hypertension

heart disease

kidney disease

liver disease

active cancer

post solid organ or bone marrow transplant

HIV/AIDS

pregnancy

breastfeeding

current smoker

current recreational drug use

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
lifestyle intervention plus phentermine-topiramatephentermine-topiramate combined with lifestyle interventionParticipants will be enrolled in a weight loss program based on lifestyle changes and the use of phentermine-topiramate to aid with weight loss
lifestyle interventionlifestyle intervention with meal replacement programParticipants will be enrolled in a weight loss program based on lifestyle changes. They will be given a 6-month subscription to a calorie-reduced meal replacement program that also offers lifestyle coaching.
Primary Outcome Measures
NameTimeMethod
change in measured and predicted resting metabolic rate during and after weight loss18 months

resting metabolic rate will be measured by indirect calorimetry every 2 months for 6 months, then every 6 months for an additional 12 month. Predicted resting metabolic rate will be calculated with a mathematical formula at the same time points

Secondary Outcome Measures
NameTimeMethod
change in circulating thyroid hormones during and after weight loss18 months

blood will be assayed for this hormone every 2 months for 6 months, then every 6 months for an additional 12 months

change in circulating AgRP during and after weight loss18 months

blood will be assayed for this hormone every 2 months for 6 months, then every 6 months for an additional 12 months

change in heart rate variability during and after weight loss18 months

blood will be assayed for this hormone every 2 months for 6 months, then every 6 months for an additional 12 months

change in circulating PYY during and after weight loss18 months

blood will be assayed for this hormone every 2 months for 6 months, then every 6 months for an additional 12 months

change in circulating leptin during and after weight loss18 months

blood will be assayed for this hormone every 2 months for 6 months, then every 6 months for an additional 12 months

change in circulating GLP-1 during and after weight loss18 months

blood will be assayed for this hormone every 2 months for 6 months, then every 6 months for an additional 12 months

change in 24h urine catecholamines during and after weight loss18 months

urine will be assayed for these hormones every 2 months for 6 months, then every 6 months for an additional 12 months

Trial Locations

Locations (1)

Medical College of Wisconsin

🇺🇸

Milwaukee, Wisconsin, United States

© Copyright 2025. All Rights Reserved by MedPath